First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Atrial Fibrillation, Persistent
Interventions
DEVICE

Pulmonary vein isolation

Arctic Front™ Cryoballoon Advance, Medtronic, for pulmonary vein isolation

DRUG

dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™

Antiarrhythmic drugs

Trial Locations (6)

41390

Institute of Medicine. Sahlgrenska Academy at University of Gothenburg, Gothenburg

75185

Department of Medical Science, Uppsala University Hospital, Uppsala

H-7624

Electrophysiology Department, Heart Institute, University of Pecs, Pécs

831 01

Div. of Arrhythmia and Pacing, National Cardiovascular Institute, Faculty of Medicine, Slovak Medical University, Bratislava

702 17

Department of Cardiology, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro

L14 3PE

Department of Cardiac Electrophysiology, Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool

All Listed Sponsors
collaborator

The Swedish Research Council

OTHER_GOV

collaborator

Erling-Persson Stiftelse

UNKNOWN

collaborator

Swedish Heart Lung Foundation

OTHER

collaborator

Uppsala University

OTHER

lead

Region Örebro County

OTHER

NCT05939076 - First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation | Biotech Hunter | Biotech Hunter